Results 61 to 70 of about 205,089 (292)

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network [PDF]

, 2013
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
A Bashey, A Eckert, A Ribas, AA Sarnaik, Armin Justich, AV Maker, AV Maker, Axel Hauschild, Beatrice Schuler-Thurner, C Robert, Carmen Loquai, Carola Berking, Caroline J. Voskens, Caroline Robert, Christina Klein, Christine Mateus, Claus Garbe, Clemens L. Bockmeyer, Daniela Göppner, Dirk Schadendorf, F Bompaire, F Fadel, F Torino, FS Hodi, FS Hodi, G Berthod, G Borodic, G Graziani, G Graziani, G Hunter, G Hunter, Gerold Schuler, Gheorghe Hundorfean, GQ Phan, GY Ku, H Gogas, H Tlaskalova-Hogenova, H. Peter Soyer, HB Wang, Imke Satzger, J Delyon, JA Blansfield, JD Wolchok, JD Wolchok, Jens Ulrich, JJ Nordlund, JM Kirkwood, JS Weber, JS Weber, JS Weber, Julia Vaubel, K Harmankaya, K Sanderson, Katharina C. Kaehler, KD Chmiel, KE Beck, L Min, LM Heinzerling, Lucie M. Heinzerling, Marc Schlaeppi, Michael Fluck, OP Hamnvik, P Attia, PA Prieto, Patrik Weder, Peter Mohr, Ralf Gutzmer, Reinhard Dummer, RH Friedline, Roger von Moos, Rüdiger Hein, S Bhatia, S Wilgenhof, S Wilgenhof, S Wilgenhof, SG Downey, Simone M. Goldinger, SM Liu, Stephan Grabbe, Sylvie Paetzold, T Bakacs, T Matsui, Tabea Wilhelm, Tanja Bergmann, Thomas Eigentler, Ullrich Keller, Uwe Trefzer, WB Breunis, WV Vogel   +88 more
core   +4 more sources

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Comparison of whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases to boost irradiation in the treatment of brain metastases from SCLC: study protocol for a randomized controlled trial

Trials, 2022
Background This study is in regard to the comparison of whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases to boost irradiation in the
Xiaofang Zhang, Tianlu Wang, Chen Yu Wang, Peng Zhao, Bo Huang, Lei He, Ying Qiu Song   +6 more
doaj   +1 more source

Radiosurgery for Five to Fifteen Brain Metastases: A Single Centre Experience and a Review of the Literature

Frontiers in Oncology, 2022
PurposeStereotactic radiosurgery (SRS) is now mainstream for patients with 1-4 brain metastases however the management of patients with 5 or more brain metastases remains controversial.
Susanne J. Rogers, Nicoletta Lomax, Sara Alonso, Tessa Lazeroms, Oliver Riesterer   +4 more
doaj   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Cystic brain metastases had slower speed of tumor shrinkage but similar prognosis compared with solid tumors that underwent radiosurgery treatment

Cancer Management and Research, 2019
Hui Wang,* Xiaoye Liu,* Xuechao Jiang, Yongchun Song, Xiaoguang Wang, Jingsheng Wang, Yang Dong, Fengtong Li, Zhiqiang Wu, Yuhan Zhang, Zhiyong Yuan Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National ...
Wang H, Liu X, Jiang X, Song Y, Wang X, Wang J, Dong Y, Li F, Wu Z, Zhang Y, Yuan Z   +10 more
doaj  

DNA Double-Strand Break Repair Genes and Oxidative Damage in Brain Metastasis of Breast Cancer [PDF]

, 2016
Background Breast cancer frequently metastasizes to the brain, colonizing a neuro-inflammatory microenvironment. The molecular pathways facilitating this colonization remain poorly understood. Methods Expression profiling of 23 matched sets of human
Aladjem, Mirit I., Badve, Sunil, Biernat, Wojciech, Czartoryska-Arlukowicz, Bogumiła, Duchnowska, Renata, Evans, Lynda, Flores, Natasha M., Fu, Haiqing, Gril, Brunilde, Gökmen-Polar, Yesim, Jassem, Jacek, Mandat, Tomasz, Mitchell, James B., Och, Waldemar, Palmieri, Diane, Qian, Yongzhen, Reed, L. Tiffany, Sledge, George, Steeg, Patricia S., Szutowicz-Zielińska, Ewa, Trojanowski, Tomasz, Woditschka, Stephan   +21 more
core   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness [PDF]

, 2019
Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do ...
Brandt, Diana, Hesse, Eric, Pamperin, Jenny, Saito, Hiroaki, Schröder, Saskia, Taipaleenmäki, Hanna   +5 more
core   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source